|
KMID : 0617319970060010057
|
|
Journal of Pharmacetical Sceiences Ewha Womans University
1997 Volume.6 No. 1 p.57 ~ p.60
|
|
|
6-[(N-2,3-Dichlorophenyl)amino]-7-Chloro-5,8-Quinoline-dione Treatment of Candidiasis in Normal Mice
|
|
유충규:Ryu Chung-Kyu
김동현:Kim Dong-Hyun/김도희:Kim Do-Hee/이인경:Lee In-Kyung/김성희:Kim Sung-Hee
|
|
|
Abstract
|
|
|
|
6-[(N-2,3-Dichlorophenyl)amino]-7-chloro-5,8-quinolinedione (RCK11) was tested for in vivo antifungal activities in the treatment of systemic infection with Candida albicans in normal mice compared with ketoconazole. The therapeutic potential of RCK11 had been assessed by evaluating their activities (survival rates) against systemic infections in normal mice. ED_50 of in-traperitoneally administered RCK11 was 0.10±0.01 ㎎/㎏ but that of ketoconazole had 8.00±0.73 ㎎/㎏ respectively. When RCK11 was administered intravenously at the ED_50 (0.10 ㎎/㎏), the colony counts of Candida albicans in the liver after 7 days and 14 days were reduced as likely as ketoconazole at the ED_50(8.00 ㎎/㎏), and the better survival rates than ketoconazole were achieved after 14 days. The results suggest that RCK11 may be a potent antifungal agent.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|